Diversity of binary toxin positive Clostridioides difficile in Korea.
Humans
Clindamycin
/ pharmacology
Moxifloxacin
/ pharmacology
Clostridioides difficile
Clostridioides
Multilocus Sequence Typing
Drug Resistance, Bacterial
/ genetics
Anti-Bacterial Agents
/ pharmacology
Toxins, Biological
Microbial Sensitivity Tests
Republic of Korea
/ epidemiology
Clostridium Infections
/ drug therapy
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
11 01 2023
11 01 2023
Historique:
received:
18
08
2022
accepted:
06
01
2023
entrez:
11
1
2023
pubmed:
12
1
2023
medline:
14
1
2023
Statut:
epublish
Résumé
The objective of this study is to determine the trend and diversity of binary toxin-positive Clostridioides difficile over 10 years in Korea. Binary toxin-positive strains were selected from a tertiary hospital in Korea in 2009-2018. The multi-locus sequence typing and antibiotic susceptibility test were performed. Among the 3278 isolates in 2009-2018, 58 possessed binary toxin genes (1.7%). The proportion of CDT- positive isolates was 0.51-4.82% in 2009-2018, which increased over the 10-year period (P = 0.023). Thirteen sequence types (STs) were identified; ST5 (14 [24%]), ST11 (11 [19%]), ST221 (10 [17%]), ST201 (7 [12%]) and ST1 (5 [9%]) were popular. All 58 isolates were susceptible to vancomycin and piperacillin/tazobactam, and clindamycin and moxifloxacin were active in 69.0% and 62% of isolates, respectively. ST1 strains were resistant to several antibiotics, including moxifloxacin (80%), clindamycin (60%) and rifaximin (60%). Moreover, four of five ST1 presented a metronidazole minimum inhibitory concentration of 4 µg/mL. Moxifloxacin resistance was highest (72.3%) for ST11. In conclusion, binary toxin-positive strains are non-prevalent in Korea and involve diverse STs. ST1 strains were resistant to several antibiotics.
Identifiants
pubmed: 36631661
doi: 10.1038/s41598-023-27768-0
pii: 10.1038/s41598-023-27768-0
pmc: PMC9834304
doi:
Substances chimiques
Clindamycin
3U02EL437C
Moxifloxacin
U188XYD42P
Anti-Bacterial Agents
0
Toxins, Biological
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
576Informations de copyright
© 2023. The Author(s).
Références
Gut Pathog. 2019 Nov 04;11:54
pubmed: 31700548
Infect Genet Evol. 2012 Oct;12(7):1577-85
pubmed: 22705462
Clin Infect Dis. 2008 Nov 1;47(9):1162-70
pubmed: 18808358
J Korean Med Sci. 2009 Jun;24(3):520-4
pubmed: 19543521
J Clin Microbiol. 2010 Mar;48(3):770-8
pubmed: 20042623
Int J Antimicrob Agents. 2009 Nov;34(5):492-3
pubmed: 19464857
J Clin Microbiol. 2008 Mar;46(3):1157; author reply 1158
pubmed: 18326836
FEMS Microbiol Lett. 2000 May 15;186(2):307-12
pubmed: 10802189
Eur J Clin Microbiol Infect Dis. 2021 Dec;40(12):2459-2478
pubmed: 34427801
Infect Chemother. 2013 Jun;45(2):175-83
pubmed: 24265965
Gut Microbes. 2014 Jan-Feb;5(1):15-27
pubmed: 24253566
J Infect. 2011 May;62(5):355-62
pubmed: 21396957
Lancet Infect Dis. 2010 Jun;10(6):395-404
pubmed: 20510280
Nat Commun. 2020 Jan 30;11(1):598
pubmed: 32001686
Emerg Infect Dis. 2011 Jun;17(6):976-82
pubmed: 21749757
PLoS One. 2016 Nov 18;11(11):e0166159
pubmed: 27861606
Gut Pathog. 2017 Aug 7;9:42
pubmed: 28794800
Adv Exp Med Biol. 2018;1050:137-159
pubmed: 29383668
Infect Drug Resist. 2018 Aug 15;11:1197-1203
pubmed: 30147348
Clin Infect Dis. 2014 May;58(10):1394-400
pubmed: 24604900
Clin Microbiol Infect. 2008 Nov;14(11):1057-64
pubmed: 19040478
Ann Med Interne (Paris). 1998 Sep;149(5):261-6
pubmed: 9791558
Emerg Microbes Infect. 2019;8(1):1553-1562
pubmed: 31662120
Infect Dis Ther. 2018 Mar;7(1):39-70
pubmed: 29441500
Front Microbiol. 2018 Apr 30;9:845
pubmed: 29760687
J Clin Microbiol. 1989 Oct;27(10):2386-7
pubmed: 2685035
N Engl J Med. 2005 Dec 8;353(23):2433-41
pubmed: 16322603
Mol Biol Evol. 1993 May;10(3):512-26
pubmed: 8336541